The promise and pitfalls of long-acting injectable agents for HIV prevention.
about
Prevention strategies for blood-borne viruses-in the Era of vaccines, direct acting antivirals and antiretroviral therapyHIV disease progression among women following seroconversion during a tenofovir-based HIV prevention trialLong-acting slow effective release antiretroviral therapy.Willingness of community-recruited men who have sex with men in Washington, DC to use long-acting injectable HIV pre-exposure prophylaxisStrengths, weaknesses, opportunities and challenges for long acting injectable therapies: Insights for applications in HIV therapy.Risk Perception, Sexual Behaviors, and PrEP Adherence Among Substance-Using Men Who Have Sex with Men: a Qualitative Study.Analysis of HIV Integrase Resistance in Black Men Who Have Sex with Men in the United States.Long Acting Ionically Paired Embonate Based Nanocrystals of Donepezil for the Treatment of Alzheimer's Disease: a Proof of Concept Study.Projections of non-communicable disease and health care costs among HIV-positive persons in Italy and the U.S.A.: A modelling study.Multimodal Theranostic Nanoformulations Permit Magnetic Resonance Bioimaging of Antiretroviral Drug Particle Tissue-Cell Biodistribution.Pharmacokinetics of a Long-Acting Nanoformulated Dolutegravir Prodrug in Rhesus Macaques.Development of an oral once-weekly drug delivery system for HIV antiretroviral therapy.Innate Immune Activation by cGMP-AMP Nanoparticles Leads to Potent and Long-Acting Antiretroviral Response against HIV-1.Investigational HIV integrase inhibitors in phase I and phase II clinical trials.Measuring Acceptability and Preferences for Implementation of Pre-Exposure Prophylaxis (PrEP) Using Conjoint Analysis: An Application to Primary HIV Prevention Among High Risk Drug Users.Home-based pre-exposure prophylaxis (PrEP) services for gay and bisexual men: An opportunity to address barriers to PrEP uptake and persistence.Are Anal Sex Roles Associated with Preferences for Pre-Exposure Prophylaxis Administration Modalities Among Men Who Have Sex with Men?Creation of a long-acting nanoformulated dolutegravir.Frequent cross-resistance to rilpivirine among subtype C HIV-1 from first-line antiretroviral therapy failures in South Africa.Harnessing nanostructured systems for improved treatment and prevention of HIV disease
P2860
Q28076466-913C8136-79A6-472F-84F9-A8EE1A2DBFA3Q33848307-3AC71F00-0A02-4FD1-8981-457B513E2FC3Q36262152-B423E14E-5785-4808-82EC-FF39D09D7947Q38615185-6FC4DFD2-9B0F-497F-A036-52CC71D86E2FQ38750666-B0ED999E-0D88-46A0-BA65-6337318ECA44Q40186272-511D267F-9C1F-4D22-83FF-127AD5FDA874Q40255060-714650F5-7A32-42CD-B8FA-3E08317A5996Q42798295-460AA0F8-0BC7-4E6E-8D61-4556A62879B6Q46442521-52CBE73A-DF94-43D6-99C5-F32341D248F9Q47095093-DD88D615-3CE4-44A3-B759-D8E6D3810393Q47142890-7C59E2BC-EA5E-4B71-AF41-12FD935829F8Q47377243-9611F0E8-7AC2-4A2D-9968-A2A9CD386434Q47586914-3DDA3669-5909-4BD6-90E3-C4F408970A6DQ47909110-BD2C8759-BFCF-4469-AE08-17E98E08008FQ48147782-7F296D4A-5F1F-433A-AF0F-EFA33292DF9EQ48342302-859D2FE8-7449-4281-9D9D-C5F372D89CD7Q49384599-4B89C422-25CF-4DC5-B785-57618EF0FE05Q50051618-EC356F13-C5AC-4C24-A2F6-10182D26EBB1Q52642470-DDCEA2F0-DDF8-4085-990E-ED96AD0E2BF2Q56992437-96974727-1B4F-4000-978B-2CF0B77BCAF7
P2860
The promise and pitfalls of long-acting injectable agents for HIV prevention.
description
2016 nî lūn-bûn
@nan
2016 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
name
The promise and pitfalls of long-acting injectable agents for HIV prevention.
@ast
The promise and pitfalls of long-acting injectable agents for HIV prevention.
@en
type
label
The promise and pitfalls of long-acting injectable agents for HIV prevention.
@ast
The promise and pitfalls of long-acting injectable agents for HIV prevention.
@en
prefLabel
The promise and pitfalls of long-acting injectable agents for HIV prevention.
@ast
The promise and pitfalls of long-acting injectable agents for HIV prevention.
@en
P2093
P2860
P1476
The promise and pitfalls of long-acting injectable agents for HIV prevention.
@en
P2093
Marybeth McCauley
Raphael J Landovitz
Ryan Kofron
P2860
P304
P356
10.1097/COH.0000000000000219
P577
2016-01-01T00:00:00Z